Dallas, TX (PRWEB) February 14, 2013
The prescription drug resource center DrugRisk.com is alerting patients taking the birth control drugs Yaz or Yasmin of updated information added to the site which shows those who suffer blood clots after using the medication may still be eligible for settlements from Bayer.
“The goal of DrugRisk is to improve medication safety by providing patients with the latest warnings, recalls and legal action related to popular drugs and medical devices. In the case of Yaz, many patients who think their case has expired can still seek legal help,” explains DrugRisk representative Ryan Mayer.
The resource center has added warnings for the Bayer drugs Yaz and Yasmin from experts like the American College of Obstetricians and Gynecologists, who stated that birth control pills containing drospirenone may have a higher risk for blood clots.*
DrugRisk has added information showing that, in the wake of warnings over blood clots, thousands of patients in the U.S. have filed a Yaz lawsuit over related conditions like pulmonary embolism or DVT, which have been consolidated in a special federal Multi-District Litigation court in Illinois.**
However, many visitors to the site believe they no longer have time to file a claim.
Now, the resource center has added the latest financial information from Bayer, which shows the company has set aside $750 million to continue settlement of Yaz lawsuits. So far, they have reached as many as 3,500 Yaz settlements, at an average of nearly $214,000 per case.*** Therefore, those who have yet to file a claim can still seek help.
Anyone who suffered a blood clot, DVT, stroke or Pulmonary Embolism after taking Yaz or Yasmin is urged to contact the Drug Risk Resource Center or speak with a lawyer about their legal options.
However, the Drug Risk Resource Center cautions that victims should seek a lawyer with experience in defective drug litigation, and only recommends lawyers and law firms who have already settled Yaz lawsuits.
For more information on the research, side effects and litigation news related to Yaz and other drugs, or to speak with a lawyer, visit http://www.DrugRisk.com.
*Chicago Tribune October 24, 2012, “Newer Pill has low blood clot risk: ob-gyn group”
**Yasmin and Yaz (Drospirenone) Marketing, Sales Practices and Products Liability Litigation (MDL No. 2100, Southern District Illinois).
***Bayer Interim Financial Statement, Legal Notes and Business Development, September 30, 2012